Company Profile
4D Molecular Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- FDMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
13.84 USD (-3.28%)
Close
Last updated: October 1, 2026
485M USD
Market cap
Why the stock is moving
The latest monitored company update is “4DMT to Host Investor Day on October 21, 2026.” The corresponding closing-price reaction is not yet available.
Company overview
Genetic Medicines Company
4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids.
4D-150 Retinal Franchise
4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule. It is being developed for wet age-related macular degeneration and diabetic macular edema with the goal of providing durable control after a single administration.
Late-Stage Ophthalmology Development
The 4FRONT pivotal program evaluates 4D-150 in wet age-related macular degeneration, while a separate Phase 3 strategy is advancing in diabetic macular edema. These studies position ophthalmology as the company's principal near-term value driver.
Broader Retinal Pipeline
4D-175 is being developed for geographic atrophy and extends the platform beyond VEGF-driven retinal disease. The program reflects the company's ability to design vectors and payloads for additional degenerative eye conditions.
Aerosol Gene Therapy for Cystic Fibrosis
4D-710 is an inhaled gene therapy intended to deliver a functional CFTR transgene to airway cells. The program targets people with cystic fibrosis who may not benefit adequately from existing CFTR modulators.
Future catalysts
- Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026.
- Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026.
- Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026.
- Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of 2027.
- Topline results from the 4FRONT-2 pivotal study of 4D-150 in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of 4D Molecular Therapeutics, Inc. (FDMT)?
4D Molecular Therapeutics, Inc. (FDMT) most recently closed at 13.84 USD, a -3.28% move versus the previous session.
What is the market cap of 4D Molecular Therapeutics, Inc. (FDMT)?
4D Molecular Therapeutics, Inc. currently has a market capitalization of 485M USD on BioPharmSignal.
What does 4D Molecular Therapeutics, Inc. do?
Genetic Medicines Company 4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids. 4D-150 Retinal Franchise 4D-150 is an...
On which exchange is FDMT stock listed?
4D Molecular Therapeutics, Inc. (FDMT) is associated with NASDAQ, United States, Biopharma.
What is VEGF-C?
4D-150 Retinal Franchise 4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule.
Which conditions is 4D Molecular Therapeutics, Inc. targeting with VEGF-C?
4D Molecular Therapeutics, Inc. is associated with ophthalmology, genetic disease based on its company overview and current catalyst commentary.
How does 4D Molecular Therapeutics, Inc. describe recent progress with VEGF-C?
Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026. Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026. Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026. Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of...
What is aflibercept?
4D-150 Retinal Franchise 4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule.